Mundipharma set to provide innovative cold treatment for Adults and Children in new markets across the Middle East, Turkey and Africa region

Dubai, UAE, January 17, 2019:  Mundipharma, the maker of the BETADINETM range of products, announced expansion of the partnership with Marinomed Biotech to extend their rights for the Carragalose® based Nasal Sprays and Lozenges in additional markets across the Middle East, Turkey and Africa (META). 

The deal will aim to further extend marketing of Marinomed’s products which have shown to significantly reduce disease duration and reduce relapses and help more adults and children suffering from the symptoms of the disease in additional markets across the META region.

The common cold is a viral infection that affects adults twice per year on average. The impact is greater for children who can typically contract them up to five to seven times per year due to their exposure at school and the playground.

The new BETADINE™ COLD DEFENCE  is a natural product with anti-viral effects that helps reduce duration of colds in adults and children.1-4 It is delivered as a nasal spray and contains the ingredient iota-carrageenan, also called Carragelose®. It is available in adult and children’s formulations and is recommended for use at the first sign of cold symptoms.

Several large scale clinical trials involving close to 600 adult and pediatric patients were conducted to evaluate the efficacy and safety of the nasal spray. The analysis of children and adults suffering from virus-confirmed common cold after two randomized, double-blind, placebo-controlled trials the nasal spray appeared as an effective treatment of common cold.1-4

Ashraf Allam, Vice President of Mundipharma Middle East, Turkey & Africa said “Every year the common cold and flu negatively impact lives of the families. BETADINE™ COLD DEFENCE  will help adults and children1-4 overcome the early symptoms of cold and may prevent the progression of the disease.

“Making BETADINE™ COLD DEFENCE  range accessible in other countries across META region is a part of Mundipharma’s commitment of making the latest and most effective treatments available to our patients and help families lead a healthier, happier life” – he added.